GlassScriptPhysician profile
Theodore B Handrup
NPI 1073594974
$8,006.49
in general payments reported to CMS, 2019-2025
22 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,296 · 2020: $663 · 2021: $1,546 · 2022: $910 · 2023: $1,113 · 2024: $1,325 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,480 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,479.87 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,331.61 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,008.49 | 2019-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $781.68 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $704.69 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $575.81 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $571.75 | 2021-2023 | Qelbree |
| Janssen Pharmaceuticals, INC | $436.63 | 2019-2025 | Spravato |
| Axsome Therapeutics, INC. | $409.57 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $386.07 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $339.97 | 2019-2022 | |
| Allergan, INC. | $304.93 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $283.24 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $210.68 | 2022-2025 | Lybalvi |
| Corium, LLC | $206.64 | 2023-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $101.28 | 2022-2023 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $74.49 | 2019 | |
| Vanda Pharmaceuticals INC. | $67.57 | 2024 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.27 | 2021-2025 | Caplyta |
| Bausch Health US, LLC | $51.02 | 2020-2022 | |
| Almatica Pharma LLC | $40.78 | 2021-2022 | |
| Tempus Ai, INC | $31.32 | 2024 | |
| Vertical Pharmaceuticals, LLC | $30.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Handrup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.